About: ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer
Creator	Douillard, Jean-Yves Lordick, Florian Pentheroudakis, George Stintzing, Sebastian Vecchione, Loredana
Source	Medline; PMC
abstract	COVID-19 pandemic challenges health system capacities in many countries. National healthcare services have to manage unexpected shortage of healthcare resources that have to be reallocated according to the principles of fair and ethical prioritisation, in order to maintain the highest levels of care to all patients, ensure the safety of patients and healthcare workers and save as many lives as possible. Beyond that, cancer care services have to pursue restructuring, following the same evidence-based dispositions. In this article, we propose guidance to the management of colorectal cancer during the pandemic, prioritised according to a three-tiered framework, based on expert clinical judgement and magnitude of benefit expected from specific interventions. Since the availability of resources for diagnostic procedures, surgery and postoperative care, systemic therapy and radiotherapy may differ, authors did separate prioritisation analyses. The impact of postponing or abrogating cancer interventions on outcomes according to a high, medium or low priority scale, is outlined and discussed. The implementation of healthcare services using telemedicine is explored: it reveals itself as functional and effective for limiting patients’ need to travel to centres and thereby has the potential to reduce diffusion of severe acute respiratory syndrome coronavirus 2. Colorectal cancer demands a considerable amount of medical resources. Therefore, the redefinition of its diagnostic and therapeutic algorithms with a rigorous method is crucial in order to ensure the highest quality of continuum of care in the broader context of the pandemic and the challenged healthcare systems.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1136/esmoopen-2020-000826
bibo:pmid	32457036
has license	cc-by-nc
sha1sum (hex)	16bcbf3d3b953c1f6a1c04c2e555427ee6a02d61
schema:url	https://doi.org/10.1136/esmoopen-2020-000826
resource representing a document's title	ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer
has PubMed Central identifier	PMC7276236
has PubMed identifier	32457036
schema:publication	ESMO Open
resource representing a document's body	covid:16bcbf3d3b953c1f6a1c04c2e555427ee6a02d61#body_text
is schema:about of	named entity 'relapse' named entity 'neoadjuvant' named entity 'COVID' named entity 'era' named entity 'COVID-19' named entity 'colorectal cancer' named entity 'Open access' named entity 'colon cancer' named entity 'palliative' named entity 'intestinal occlusion' named entity 'Secondary prevention' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'relapse' named entity 'COVID-19' named entity 'oncologists' named entity 'healthcare facilities' named entity 'bisphosphonates' named entity 'public health crisis' named entity 'comorbidities' named entity 'blood test' named entity 'respiratory insufficiency' named entity 'Ontario' named entity 'panitumumab' named entity 'curative intent' named entity 'Blood tests' named entity 'healthcare personnel' named entity 'tumour' named entity 'telemedicine' named entity 'critically ill patients' named entity 'breast-cancer' named entity 'TAS-102' named entity 'asymptomatic patients' named entity 'colorectal cancer' named entity 'Colorectal cancer' named entity 'rectal cancer' named entity 'Capecitabine' named entity 'liver metastasis' named entity 'diagnostic procedures' named entity 'blood tests' named entity 'intravenous' named entity 'WHO' named entity 'European community' named entity 'colon cancer' named entity 'radiotherapy' named entity 'oncologists' named entity 'healthcare workers' named entity 'ascites' named entity 'COVID' named entity 'endoscopic' named entity 'tumour' named entity 'COVID-19' named entity 'oncologist' named entity 'virus' named entity 'endoscopy' named entity 'prognostic' named entity 'COVID-19 pandemic' named entity 'oncology' named entity 'WHO' named entity 'follow-up' named entity 'high-risk' named entity 'endoscopy' named entity 'adjuvant treatment' named entity 'surgical procedures' named entity 'endoscopy' named entity 'granulocyte' named entity 'ascites' named entity '5-FU' named entity 'neutropenia' named entity 'intestinal occlusion' named entity 'gastrointestinal bleeding' named entity 'COVID-19 pandemic' named entity 'WHO' named entity 'neoadjuvant' named entity 'psychological support' named entity 'immunosuppressed' named entity 'radiation therapy' named entity 'healthcare systems'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software